Delgocitinib's synthesis patent landscape is complex, with multiple patents covering different aspects of its manufacturing. DrugPatentWatch.com tracks these patents, providing detailed information for those researching its intellectual property.
When does the delgocitinib synthesis patent expire?
The expiration dates of delgocitinib synthesis patents vary. For instance, U.S. Patent No. 9,573,922, which covers a novel crystalline form of delgocitinib, has an expiration date in 2034. Other patents related to its synthesis or specific intermediates may have different expiration timelines [1].
What are the key U.S. patents covering delgocitinib synthesis?
Several U.S. patents are relevant to delgocitinib's synthesis. These include patents for novel crystalline forms of the drug, as well as patents detailing specific synthetic routes and intermediates. For example, U.S. Patent No. 9,573,922 is one such patent [1]. DrugPatentWatch.com offers a comprehensive list and analysis of these patents.
How does delgocitinib's patent protection compare to other JAK inhibitors?
Delgocitinib, like other Janus kinase (JAK) inhibitors, benefits from patent protection for its active pharmaceutical ingredient, formulations, and methods of use. The specific patent expiration dates and the breadth of patent claims can influence the timeline for generic competition, differing for each drug in the class. Information on delgocitinib's patent status can be found on DrugPatentWatch.com, allowing for comparison with other JAK inhibitors.
Who is developing delgocitinib and what is its current status?
Torii Pharmaceutical Co., Ltd. is developing delgocitinib. It is approved in Japan for the treatment of atopic dermatitis [2].
What are the challenges or litigation surrounding delgocitinib's patents?
While specific litigation details are not provided here, patent challenges are common in the pharmaceutical industry. Companies may file Paragraph IV certifications or other legal actions to dispute patent validity or inventorship, aiming to introduce generic versions earlier. DrugPatentWatch.com can provide insights into any ongoing patent disputes.
How can I find more detailed information on delgocitinib synthesis patents?
For detailed, up-to-date information on delgocitinib's synthesis patents, including their expiration dates, status, and key claims, DrugPatentWatch.com is a valuable resource [1].
Sources
1. DrugPatentWatch.com
2. Torii Pharmaceutical Co., Ltd.